/

Empresas

Al

No verificado

Alzamend Neuro, Inc.

Sobre qué escribimos

FarmacéuticaIndustriaMedicina - VariosPsiquiatríaSalud

14 Comunicados de prensa

Ver todos los comunicados de prensa

19/02/2025

Multimedia

Industria

Psiquiatría

Salud

Medicina - Varios

Farmacéutica

Biotecnología

Alzamend Neuro Announces Completion of a Novel Head Coil by Tesla for Measuring Brain Structure Lithium Levels in Five Upcoming Phase II Clinical Trials at Massachusetts General Hospital

Fuente

Alzamend Neuro, Inc.

Editor

1.00

0

15/01/2025

Eventos

Industria

Psiquiatría

Salud

Sanidad

Ciencia

Farmacéutica

Alzamend Neuro to Present at the Sequire Investor Summit

Fuente

Alzamend Neuro, Inc.

Editor

1.00

0

18/12/2024

Eventos

Industria

Psiquiatría

Salud

Medicina - Varios

Farmacéutica

Biotecnología

Alzamend Neuro to Present Non-Clinical Data Update at the Society of Toxicology 2025 Annual Meeting and ToxExpo

Fuente

Alzamend Neuro, Inc.

Editor

1.00

0

12/12/2024

Ciencia

Farmacéutica

Sanidad

Salud

Psiquiatría

Medicina - Varios

Mercado de valores

Industria

Alzamend Neuro Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs

Fuente

Alzamend Neuro, Inc.

Editor

1.00

0

19/11/2024

Ciencia

Farmacéutica

Sanidad

Salud

Psiquiatría

Medicina - Varios

Industria

Alzamend Neuro Announces Full Data Set from its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures between AL001 and Lithium Carbonate in Alzheimer’s Transgenic Mice

Fuente

Alzamend Neuro, Inc.

Editor

1.00

0

16/10/2024

Industria

Biotecnología

Psiquiatría

Salud

Farmacéutica

Medicina - Varios

Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s

Fuente

Alzamend Neuro, Inc.

Editor

1.00

0

15/10/2024

Ciencia

Biotecnología

Farmacéutica

Sanidad

Salud

Psiquiatría

Alzamend Neuro Regains Compliance with Nasdaq Listing Standards

Fuente

Alzamend Neuro, Inc.

Editor

1.00

0

10/10/2024

Web y redes sociales

Eventos

Psiquiatría

Material médico sanitario

Salud

Farmacéutica

Biotecnología

Alzamend Neuro CEO Stephan Jackman to Participate in the Maxim Group’s Virtual Healthcare Conference

Fuente

Alzamend Neuro, Inc.

Editor

1.00

0

19/08/2024

Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder

Fuente

Alzamend Neuro, Inc.

Editor

1.00

0

12/08/2024

Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Major Depressive Disorder

Fuente

Alzamend Neuro, Inc.

Editor

1.00

0

Seguidores

0

Compatibilidad

0